GLP-1 receptor agonists (GLP-1RAs) were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management ...

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

FDA ends GLP-1 drug shortage. Concerns over safety, counterfeit drugs, and high cost of brand-name versions persist; ...

For patients with type 2 diabetes, glucagon-like peptide-1 receptor agonist use is associated with a reduced risk for developing hematologic cancers compared with insulin and metformin use.

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...

Preoperative glucagon-like peptide-1 receptor agonist use is not associated with short-term postoperative aspiration pneumonia.

HealthDay News — Stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment 14 days before total joint arthroplasty can minimize risks for complications, according to a study presented at ...

GLP-1 receptor agonists show promise in treating alcohol addiction by modulating reward pathways and reducing cravings, offering a novel therapeutic approach.

Natural products industry companies share overviews on the latest science on their branded ingredients and products to ...

Mechanism of action describes the process by which a molecule, such as a drug, functions to produce a pharmacological effect. A drug’s mechanism of action may refer to its effects on a ...

The first reason is because the mechanism of action [MOA] of using a GLP-1 Receptor ... short amount of 12-weeks already proved that its GLP-1 RA MET-097i already attained a mean placebo adjusted ...

Adults aged 66 years or older with T2D initiating treatment with a GLP-1 RA were propensity score-matched to those initiating treatment with an SGLT-2i (14,665 matched pairs) or a DPP-4i (13,711 ...